Enveric Biosciences Inc (ENVB)

$5.04 +1.02 (25.37%)
Market Cap 7.59M
Revenue (ttm) 0.00
Net Income (ttm) -8.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 41,942,500
Avg Vol 4,853,830
Day's Range N/A - N/A
Shares Out 1.89M
Stochastic %K 54%
Beta 0.34
Analysts Strong Buy
Price Target $10.00

Company Profile

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules...

Industry: Biotechnology
Sector: Healthcare
Address:
245 First Street, Riverview II 18 th Floor, Cambridge, United States
TeamBullish
TeamBullish Apr. 25 at 6:26 PM
Top setups for next weeks session! $CTNT $SMX $ENVB $ELPW $SCNI https://youtu.be/zwZYVAF4w0o
1 · Reply
Sw1ngb0t
Sw1ngb0t Apr. 25 at 5:49 PM
$ENVB $13
0 · Reply
RoyalImperial
RoyalImperial Apr. 25 at 5:20 PM
MITQ ✅ Getting ready for a big breakout next week, keep eyes on it! Latest news + contracts rolling in Low float (6M) NO dilution Record earnings trend 📈. MITQ super undervalued->The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $AKAN $ENVB $TRT $MXL on watch.
0 · Reply
Maydate8
Maydate8 Apr. 25 at 5:04 PM
$ENVB Need a bounce
0 · Reply
Luckyjs38
Luckyjs38 Apr. 25 at 3:41 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Apr. 25 at 3:41 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Apr. 25 at 3:41 PM
$ENVB Will become a household name 🇺🇸❤️
0 · Reply
Treechain
Treechain Apr. 25 at 2:42 PM
$ENVB just the fact that most of the shares have traded higher than this should make Monday an easy move up from after hours lows. Do some research on carboxylate acid , they have combined with psilocybin next be trials fda NDA news and off to $100 per share
1 · Reply
Toptradersam
Toptradersam Apr. 25 at 2:36 PM
If you’re holding $ENVB, this is one you don’t want to ignore 👀 The setup is shifting, volume is telling a story, and Monday could bring some decisive action. https://www.youtube.com/watch?v=ZfGHPBYmDis
0 · Reply
Luckyjs38
Luckyjs38 Apr. 25 at 3:39 AM
$ENVB this is not a day trade or swing trade this is an investment. IND soon and from there its history
0 · Reply
Latest News on ENVB
What's Going On With Enveric Biosciences Stock On Friday?

Apr 24, 2026, 2:13 PM EDT - 1 day ago

What's Going On With Enveric Biosciences Stock On Friday?

Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum

Apr 21, 2026, 8:00 AM EDT - 4 days ago

Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum

Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order

Apr 20, 2026, 3:26 PM EDT - 4 days ago

Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

Apr 20, 2026, 6:43 AM EDT - 5 days ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX GHRS HELP

Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 17, 2026, 6:28 PM EDT - 7 days ago

Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 16, 2026, 8:00 PM EDT - 8 days ago

Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

Mar 31, 2026, 8:00 AM EDT - 25 days ago

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

Mar 27, 2026, 5:40 PM EDT - 4 weeks ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

Enveric Biosciences Announces Registration of Five Trademarks

Mar 18, 2026, 8:00 AM EDT - 5 weeks ago

Enveric Biosciences Announces Registration of Five Trademarks

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Feb 25, 2026, 8:00 AM EST - 2 months ago

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Feb 19, 2026, 8:00 AM EST - 2 months ago

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Jan 29, 2026, 8:00 AM EST - 3 months ago

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jan 28, 2026, 5:00 PM EST - 3 months ago

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jan 28, 2026, 8:00 AM EST - 3 months ago

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences Announces Patent Issuance

Dec 29, 2025, 8:00 AM EST - 4 months ago

Enveric Biosciences Announces Patent Issuance

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 12, 2025, 4:46 PM EST - 4 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 11, 2025, 1:43 PM EST - 4 months ago

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Dec 9, 2025, 8:00 AM EST - 4 months ago

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Dec 4, 2025, 8:00 AM EST - 5 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Nov 26, 2025, 8:00 AM EST - 5 months ago

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Nov 14, 2025, 4:05 PM EST - 5 months ago

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Enveric Biosciences Announces Reverse Stock Split

Oct 23, 2025, 8:00 AM EDT - 6 months ago

Enveric Biosciences Announces Reverse Stock Split

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Oct 16, 2025, 8:30 AM EDT - 6 months ago

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Oct 15, 2025, 8:00 AM EDT - 6 months ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Oct 14, 2025, 9:00 AM EDT - 6 months ago

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Oct 2, 2025, 8:45 AM EDT - 7 months ago

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 18, 2025, 4:30 PM EDT - 7 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 9:24 AM EDT - 7 months ago

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Sep 17, 2025, 8:00 AM EDT - 7 months ago

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Sep 16, 2025, 8:45 AM EDT - 7 months ago

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 8 months ago

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Sep 2, 2025, 8:30 AM EDT - 8 months ago

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Aug 28, 2025, 8:30 AM EDT - 8 months ago

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Aug 14, 2025, 8:00 AM EDT - 9 months ago

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Jul 23, 2025, 8:03 AM EDT - 9 months ago

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Jul 15, 2025, 9:03 AM EDT - 10 months ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Jun 24, 2025, 9:03 AM EDT - 10 months ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Jun 16, 2025, 10:46 AM EDT - 11 months ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Jun 10, 2025, 9:03 AM EDT - 11 months ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Jun 3, 2025, 9:00 AM EDT - 11 months ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 28, 2025, 9:03 AM EDT - 11 months ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 20, 2025, 8:00 AM EDT - 1 year ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

May 14, 2025, 4:15 PM EDT - 1 year ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Enveric Biosciences Participating in BIO-Europe Spring®

Mar 17, 2025, 1:40 PM EDT - 1 year ago

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Mar 6, 2025, 10:00 AM EST - 1 year ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Enveric Biosciences CEO Issues Letter to Shareholders

Feb 27, 2025, 9:30 AM EST - 1 year ago

Enveric Biosciences CEO Issues Letter to Shareholders

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Feb 25, 2025, 1:30 PM EST - 1 year ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Feb 4, 2025, 8:00 AM EST - 1 year ago

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Enveric Biosciences Announces Closing of $5 Million Public Offering

Feb 3, 2025, 5:00 PM EST - 1 year ago

Enveric Biosciences Announces Closing of $5 Million Public Offering

TeamBullish
TeamBullish Apr. 25 at 6:26 PM
Top setups for next weeks session! $CTNT $SMX $ENVB $ELPW $SCNI https://youtu.be/zwZYVAF4w0o
1 · Reply
Sw1ngb0t
Sw1ngb0t Apr. 25 at 5:49 PM
$ENVB $13
0 · Reply
RoyalImperial
RoyalImperial Apr. 25 at 5:20 PM
MITQ ✅ Getting ready for a big breakout next week, keep eyes on it! Latest news + contracts rolling in Low float (6M) NO dilution Record earnings trend 📈. MITQ super undervalued->The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $AKAN $ENVB $TRT $MXL on watch.
0 · Reply
Maydate8
Maydate8 Apr. 25 at 5:04 PM
$ENVB Need a bounce
0 · Reply
Luckyjs38
Luckyjs38 Apr. 25 at 3:41 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Apr. 25 at 3:41 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Apr. 25 at 3:41 PM
$ENVB Will become a household name 🇺🇸❤️
0 · Reply
Treechain
Treechain Apr. 25 at 2:42 PM
$ENVB just the fact that most of the shares have traded higher than this should make Monday an easy move up from after hours lows. Do some research on carboxylate acid , they have combined with psilocybin next be trials fda NDA news and off to $100 per share
1 · Reply
Toptradersam
Toptradersam Apr. 25 at 2:36 PM
If you’re holding $ENVB, this is one you don’t want to ignore 👀 The setup is shifting, volume is telling a story, and Monday could bring some decisive action. https://www.youtube.com/watch?v=ZfGHPBYmDis
0 · Reply
Luckyjs38
Luckyjs38 Apr. 25 at 3:39 AM
$ENVB this is not a day trade or swing trade this is an investment. IND soon and from there its history
0 · Reply
Jumpmanz
Jumpmanz Apr. 25 at 3:36 AM
$CMPS $DFTX $ENVB $GHRS $PBM
0 · Reply
ChartChartist
ChartChartist Apr. 25 at 2:14 AM
$CHSN so good its the best. Long hold $ENVB paid twice $ISPC 50% are easy But $NWGL is the top play for Monday
0 · Reply
History101
History101 Apr. 25 at 1:16 AM
$ENVB $CMPS $GHRS $DFTX $PBM bullish article https://www.zerohedge.com/markets/fda-grants-quick-review-psychedelic-drugs-first-approvals-could-come-soon-summer
0 · Reply
SwingTradezzz
SwingTradezzz Apr. 25 at 1:08 AM
$TORO CEO Buys 2.3M shares worth 14.2M Disclosed April 24, 2026 @ 6:34PM (Today) Good Signs for Monday Open <$SKLZ $MSOS $ENVB Parabolic
0 · Reply
topstockalerts
topstockalerts Apr. 25 at 1:05 AM
$ENVB just watching how it reacts here… key spot
0 · Reply
DDUDDU
DDUDDU Apr. 25 at 12:48 AM
$ENVB Is one more pump possible here? So far, the pattern has been that the price moves sideways with decreasing volume, and then it rises. Today also looks like it’s trying to hold around $5. I’m starting to worry they might be diluting the shares
0 · Reply
___2___
___2___ Apr. 24 at 11:55 PM
$ENVB clown lol👇
0 · Reply
Alternative1
Alternative1 Apr. 24 at 11:53 PM
$ENVB this garbage will pull AUUD on Monday LMAO
0 · Reply
Stumblingbuffalo
Stumblingbuffalo Apr. 24 at 11:08 PM
$DKI $AUUD $AKAN $ENVB second tume ive seen some trting to pump this $MITQ...
0 · Reply
BullsR4run
BullsR4run Apr. 24 at 10:58 PM
$ENVB I am seating pretty on 10k share at $5.12 Anytime now!
2 · Reply
2TrustHim
2TrustHim Apr. 24 at 10:55 PM
$ENVB When TRUMP Says HE Tried it It Will FLY!!!🤣
0 · Reply
topstockalerts
topstockalerts Apr. 24 at 10:52 PM
$ENVB I almost skipped over this one earlier… glad I didn’t
0 · Reply